Investor Overview

Corporate Profile

Zai Lab (NASDAQ:ZLAB) is an innovative commercial-stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To quickly target the large, fast-growing segments of China’s pharmaceutical market and address unmet medical needs, Zai Lab’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates. Zai Lab has also built an in-house team with strong drug discovery and translational research capabilities, aiming to establish a global pipeline of proprietary drug candidates against targets in our focus areas. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its portfolio in order to impact human health worldwide.

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor & Media Contacts

Zai Lab
Ron Aldridge, Executive Director, Investor Relations
+1 (781) 434-8465
ronald.aldridge@zailaboratory.com

Lina Zhang, Senior Director, Investor Relations and Strategy
+86 136 8257 6943
lina.zhang@zailaboratory.com

Media Inquiries
Ryo Imai / Robert Flamm, Ph.D.
Burns McClellan, on behalf of Zai Lab
212-213-0006 ext. 315 / 364
rimai@burnsmc.com / rflamm@burnsmc.com

Investor Inquiries
Pete Rahmer
415-515-9763
prahmer@enduranceadvisors.com